Awaiting development: Guidance and quality standards

Showing 161 to 170 of 336

Guidance and quality standards awaiting development
Title	Type
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Machine perfusion devices for lung transplants	Health technology evaluation
Managing symptoms with an uncertain cause	Quality standard
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Health technology evaluation
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]	Technology appraisal guidance
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance